glp 1 agonists in development GLP-1 Receptor Agonist Market Size GLP-1 Agonists Market Report 2025-2033,

GoodRx reports that while satisfaction with GLP-1s for weight loss is high, costs and access issues significantly impact patient experiences.

Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration

Other oral compounds like CT-996 / RG 6652 showed a clinically meaningful weight reduction of 6-7% in four weeks among participants without T2D, and GSBR-1290 has demonstrated favourable safety, tolerability and efficacy results

Glucagon-like peptide-1 (GLP-1) is an incretin hormone mainly secreted from intestinal L cells in response to nutrient ingestion

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic poly-peptide (GIP, previously known as gastric inhibitory polypeptide) are key incretin

This may come in the form of even more severe limits on coverage of obesity meds.